Result of General Meeting

RNS Number : 0890N

Renalytix AI PLC

15 May 2020

 

Renalytix AI plc

("RenalytixAI", the "Company")

Result of General Meeting

Renalytix AI plc (LSE :   RENX ), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and to grant the Company the general authority to make market purchases of its own shares were passed. 99.99% (12,665,883 votes) of the votes were cast in favour of the resolution.

The Company is currently making the necessary court applications to enable it to proceed with the share buyback and will issue further updates at the appropriate time.

For further information, please contact:

Renalytix AI plc		www.renalytixai.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser & Broker)		Tel: [phone]
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker)		Tel: [phone]
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

 

END

 

 

ROMKKPBPDBKDCPD